Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+metastatic breast cancer (MBC)

被引：0
|
作者：
Jagiello-Gruszfeld, A.
Tjulandin, Sergei S.
Dobrovolskava, N.
Manikhas, A.
Pienkowski, T.
Knott, A.
DeSilvio, M.
Oliva, C.
机构：
[1] Nzoz Onko Med, Olsztyn, Poland
[2] Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia
[3] Russian Sci Ctr Roentgeno Radiol, Moscow, Russia
[4] St Petersburg City Oncol Dispensery, St Petersburg, Russia
[5] Inst Marii Sklodowskiej Curie, Centrum Onkol, Warsaw, Poland
[6] GlaxoSmithKline Res & Dev Ltd, London, England
[7] GlaxoSmithKline Res & Dev Ltd, Philadelphia, PA USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：246S / 246S
页数：1
相关论文
共 50 条
  • [11] Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer
    Chitapanarux, Imjai
    Kamnerdsupaphon, Pimkhuan
    Tharavichitkul, Ekasit
    Lorvidhaya, Vicharn
    Trakultivakorn, Hongsin
    Srisukho, Songpol
    Somwangprasert, Areewan
    Watcharachan, Kirati
    Sukthomya, Vimol
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (01) : 76 - 82
  • [12] Lapatinib (L) plus capecitabine (C) in HER2+metastatic breast cancer (MBC): exploratory analyses by prior therapy
    Crown, J.
    Casey, M. A.
    Cameron, D.
    Newstat, B.
    Stein, S. H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 285 - 285
  • [13] A PHASE II EVALUATION OF LAPATINIB (L) AND BEVACIZUMAB (B) IN HER2+METASTATIC BREAST CANCER (MBC)
    Dickler, M.
    Franco, S.
    Stopeck, A.
    Ma, W.
    Lyandres, J.
    Lahiri, S.
    Arbushites, M.
    Koehler, M.
    Rugo, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 65 - 65
  • [14] IMP321 and weekly paclitaxel as first-line chemoimmunotherapy for metastatic breast cancer (MBC)
    Triebel, F.
    Brignone, C.
    Grygar, C.
    Marcu, M.
    Gutierez, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [15] Baseline characteristics and first-line (1L) treatment of patients with HER2+metastatic breast cancer (MBC) from the SystHERs registry
    Kaufman, P. A.
    Hurvitz, S. A.
    O'Shaughnessy, J.
    Mason, G.
    Yardley, D. A.
    Brufsky, A.
    Rugo, H. S.
    Cobleigh, M.
    Swain, S. M.
    Tripathy, D.
    Chu, L.
    Antao, V.
    Yoo, B.
    Jahanzeb, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [16] IMP321 and Weekly Paclitaxel as First-line Chemoimmunotherapy for Metastatic Breast Cancer (MBC)
    Triebel, Frederic
    Brignone, Chrystelle
    Maya, Gutierrez
    JOURNAL OF IMMUNOTHERAPY, 2009, 32 (09) : 952 - 953
  • [17] A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+metastatic breast cancer (MBC)
    Rugo, H. S.
    Franco, S.
    Munster, P.
    Stopeck, A.
    Ma, W.
    Lyandres, J.
    Lahiri, S.
    Arbushites, M.
    Koehler, M.
    Dickler, M. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [18] Weekly paclitaxel and trastuzumab as first-line chemotherapy in patients with her-2 positive metastatic breast cancer
    Kim, Jin-Soo
    Han, Hye-Suk
    Im, Seock-Ah
    Oh, Do-Youn
    Han, Won-Shik
    Lee, Se-Hoon
    Kim, Dong-Wan
    Kim, Tae-You
    Noh, Dong-Young
    Bang, Yung-Jue
    ANNALS OF ONCOLOGY, 2006, 17 : 85 - 85
  • [19] WEEKLY PACLITAXEL (PCT) plus TRASTUZUMAB (T) AS FIRST-LINE THERAPY OF PATIENTS (PTS) WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER (MBC): A MULTICENTER RANDOMIZED PHASE II TRIAL
    Gasparini, Giampietro
    Crivellari, Diana
    Filippelli, Gianfranco
    Morabito, Alessandro
    Silingardi, Vittorio
    De Sio, Livia
    Spada, Antonella
    Papaldo, Paola
    Carillio, Guido
    Veronesi, A.
    Zancan, Matelda
    Gion, Massimo
    Caputo, Antonio
    Cognetti, Francesco
    Amadori, Dino
    ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
  • [20] WEEKLY DOCETAXEL (WEDO) AS FIRST-LINE THERAPY IN ELDERLY METASTATIC BREAST CANCER (MBC)
    Caristi, Nicola
    Maisano, Roberto
    Mare, Marzia
    Chiofalo, Giuseppe
    Picciotto, Maria
    Mafodda, Antonio
    Montalto, Erika
    Zavettieri, Maria
    La Torre, Francesco
    ANNALS OF ONCOLOGY, 2004, 15 : 19 - 20
12345